Recent news on Rapamycin

AUA 2007 - Pediatrics Basic Science  -  25 May 2007
UroToday,Abstract 720 demonstrated that Mammalian Target of Rapamycin is critical for hypoxia and stretch mediated proliferation in bladder smooth muscle.

Exelixis winning Phase I race  -  25 May 2007
BiopharmaReporter.com,This drug again inhibits PI3K but it also blocks the action of mammalian target of rapamycin (mTOR), which also is activated frequently in human tumours and

Molecules Discovered that Encourage Cells to Eat Huntington's Protein  -  May 8, 2007
Genetic Engineering News (press release),Researchers have found a way of identifying small molecules capable of inducing autophagy without the side effects seen with rapamycin.

New compounds promising candidates for neurodegenerative disease ...  -  May 9, 2007
News-Medical.net,Autophagy can be induced in mouse and fly models by administering the drug rapamycin, an antibiotic used as an immunosuppressant for transplant patients.

Harnessing cells' snacking habits to treat Huntington's  -  May 8, 2007
Cordis News,Autophagy can be stimulated in mice and flies by administering a drug called rapamycin, an antibiotic used as an immunosuppressant in transplant patients.

Hope of breakthrough in treatment of brain disorder  -  May 7, 2007
Scotsman,Scientists found a way to induce autophagy in animals with Huntingdon's by giving them an antibiotic drug, rapamycin. Their findings were published in the

May 2007 Clinical Briefs  -  May 1, 2007
U.S. Medicine,Rapamycin, an FDA-approved drug normally used to help prevent the body from rejecting organ and bone marrow transplants and also used to coat cardiac stents

Making a meal of Huntington's disease may harbour cure  -  May 8, 2007
DailyIndia.com,Mouse and fly models can be made to perform autophagy by administering the drug rapamycin. However, the drug has some side effects in the long run,

The Humble Nematode  -  May 6, 2007
Methuselah Foundation,Some folk seem a little skeptical of the whole "target of rapamycin" work, but the proof is in the pudding. Resources continue to pour into the study of

New autophagy-enhancing molecules found  -  May 8, 2007
Therapeutics Daily (subscription) (press release),However, the researchers said rapamycin -- the only known small molecule that increases autophagy -- regulates a wide range of cellular processes and would

CUSTOM II: Customizable DES "encouraging" at six months in ...  -  May 23, 2007
TheHeart.Org,The drug used on the stent is Biolimus A9 (Biosensors International), a rapamycin derivative, applied only to the surfaces of the stent that contact the

Abraxis BioScience Reports First Quarter 2007 Revenue of $212.2 ...  -  May 11, 2007
PharmaLive.com (press release),These results demonstrated that nab-rapamycin was well-tolerated, showed linear pharmacokinetics, and was highly effective against a number of tumor models

Enticing cells to 'eat' Huntington's  -  May 8, 2007
BiopharmaReporter.com,Prof Rubinsztein first discovered that an existing immunosuppressant drug, namely Wyeth's Rapamune (rapamycin/sirolimus), induced autophagy in mice and

Immune Function Clarified In Post-Transplant Cancer  -  May 3, 2007
eMaxHealth.com,...because the function of their CD4 and CD8 cells is dramatically altered by immunosuppressive drugs like cyclosporin and rapamycin," says Oberyszyn,

Hepatitis C Growth In Liver Cells Slowed By Protein  -  May 3, 2007
Medical News Today (press release),Their article is entitled "P21-activated Kinase 1 Is Activated through the Mammalian Target of Rapamycin/p70 56 Kinase Pathway and Regulates the Replication

Surgery for Acquired Cardiovascular Disease  -  May 2, 2007
The Journal of Thoracic and Cardiovascular Surgery...of mediastinal and leg wound infection or multiorgan sepsis; however, an important immunosuppressant that clearly affects wound healing is rapamycin.

Cellular protein found that interferes with hepatitis C virus ...  -  May 1, 2007
News-Medical.net,Their article is entitled ,P21-activated Kinase 1 Is Activated through the Mammalian Target of Rapamycin/p70 56 Kinase Pathway and Regulates the Replication

Sirolimus Treatment for Pulmonary Lymphangioleiomyomatosis  -  Apr 30, 2007
Annals of Internal MedicineSirolimus (rapamycin), a specific S6K1 inhibitor, abolishes LAM cell abnormal proliferation in vitro (5). Objective: To determine whether sirolimus could

The Ethical Issues of Uterine Transplantation: Debunking the ...  -  Apr 30, 2007
Student Operated Press,As for other agents, such as rapamycin and mycophenolate mofetil, their effects are still unknown. “This would currently be a highly speculative

Protein found that slows hepatitis C growth in liver cells  -  Apr 30, 2007
innovations report,Their article is entitled “P21-activated Kinase 1 Is Activated through the Mammalian Target of Rapamycin/p70 56 Kinase Pathway and Regulates the Replication

News Tips From The Journal Of Biological Chemistry  -  Apr 26, 2007
Medical News Today (press release),Article: "p21-activated Kinase 1 Is Activated through the Mammalian Target of Rapamycin/p70 S6 Kinase Pathway and Regulates the Replication of Hepatitis C

2007 BIO International Convention Exhibitor Profiles Continued, D ...  -  May 3, 2007
Genetic Engineering News (press release),Additionally, Isotechnika has developed TAFA93, a novel prodrug of the mTOR inhibitor rapamycin. TAFA93 has successfully completed Phase 1 trials.

Exelixis Files IND Application for XL765  -  26 Apr 2007
PR Newswire (press release),XL765 also inhibits mammalian target of rapamycin (mTOR), which also is activated frequently in human tumors and plays a central role in tumor cell growth.

News Tips From The Journal Of Biological Chemistry  -  26 Apr 2007
Medical News Today (press release),Article: "p21-activated Kinase 1 Is Activated through the Mammalian Target of Rapamycin/p70 S6 Kinase Pathway and Regulates the Replication of Hepatitis C

Abraxis BioScience Presents Results from Pre-Clinical Study That ...  -  Apr 19, 2007
PharmaLive.com (press release),Results from the pre-clinical study demonstrated that nab-rapamycin was well-tolerated, showed linear pharmacokinetics, and was highly effective against a

Immunosuppressant Drug Prevents Tobacco Induced Lung Cancer in Mice  -  Apr 3, 2007
PressZoom (press release),Rapamycin, an FDA-approved drug normally used to help prevent the body from rejecting organ and bone marrow transplants and also used to coat cardiac stents

Immunosuppressant Drug Prevents Tobacco Induced Lung Cancer in Mice  -  Apr 2, 2007
PharmaLive.com (press release),BETHESDA, Md., April 1, 2007--Rapamycin, an FDA-approved drug normally used to help prevent the body from rejecting organ and bone marrow transplants and

Value Of Stent-coating Drugs Questioned  -  Apr 3, 2007
Science Daily (press release)Previous research has shown that rapamycin used in drug-eluting stents (DES) successfully reduces restenosis, or repetitive narrowing of the arteries.

Anti-rejection drug could help treat a killer lung disease  -  Apr 5, 2007
49abcnews.com,Researchers are testing an anti-rejection drug, called Rapamycin, to see if the medication can restore lung function in patients with LAM.

ACC: Stent Eluting Two Drugs Offers No Extra Benefit Over One  -  Mar 27, 2007
MedPage Today,NEW ORLEANS, March 27 -- The first trial of a stent coated with two drugs -- estradiol and rapamycin -- showed no benefit over a stent eluting rapamycin

FDA Extends NDA Review of Torisel™  -  Apr 16, 2007
Cancer Consultants (press release),Torisel inhibits the mTOR (mammalian target of rapamycin) kinase, which is a protein that is involved in cellular proliferation, growth and survival.

On the LAM  -  Mar 28, 2007
Philadelphia citypaper.net,This allowed Krymskaya and other scientists to determine that the FDA-approved drug rapamycin could combat LAM because of its ability to mimic the function

Abraxis BioScience Presents Pre-Clinical Findings That Support ...  -  Apr 19, 2007
PharmaLive.com (press release),Studies are ongoing to evaluate several other therapeutic candidates that employ the nab technology including nab-docetaxel (ABI-008), nab-rapamycin mTOR

Lymphangioleiomyomatosis (LAM)  -  Mar 29, 2007
WSOCtv.com,In further research, she found an anti-rejection drug for transplant patients, called rapamycin, could inhibit the growth of LAM cells by mimicking the

Genomics Closes In On Cancer, Mutations, Somatic Or Inherited  -  Apr 16, 2007
BioWorld Online,In one trial, to test the use of rapamycin against mTOR in glioblastoma, only 15 of 154 patients ultimately met the criteria to be treated,

MacuSight(TM) to Present at IBC's 4th International Conference on ...  -  Apr 10, 2007
PR Newswire (press release),Dr. Weber's presentation will take place at 2:45 pm EDT on Tuesday, April 17th and will focus on the role of sirolimus (rapamycin) as a potential

MacuSight(TM) to Present at IBC's 4th International Conference on ...  -  Apr 10, 2007
PR-Inside.com (Pressemitteilung),...and will focus on the role of sirolimus (rapamycin) as a potential therapeutic for the treatment of a variety of serious ocular diseases and conditions,

Tentative OK for Abraxis Drug  -  Apr 19, 2007
Los Angeles Business Journal (subscription),The company plans to commence first stage clinical trials of nab-rapamycin in 2007. The company already has one brand-name drug on the market, Abraxane,

Clues To Ovarian Cancer's Deadly Secrets  -  Apr 16, 2007
Medical News Today (press release),Using the genetically engineered mice her lab developed, one preclinical study is already under way, testing an existing drug called Rapamycin.

Case 12-2007 — A 56-Year-Old Woman with Renal Failure after Heart ...  -  Apr 18, 2007
New England Journal of Medicine (subscription),Target of rapamycin (TOR) inhibitors block the cell cycle through their action on the intracytoplasmic protein TOR. There are two agents in this class,

Setback for Wyeth as FDA delays review on kidney cancer drug Torisel  -  Apr 10, 2007
Pharma Times (subscription),Torisel comes from a drug class known as mTOR (mammalian target of rapamycin) inhibitors and is the first agent of its type to be filed for approval in a

Wyeth Provides Update on FDA Review of the Torisel New Drug ...  -  Apr 9, 2007
Drug Newswire (press release),Torisel was designed to inhibit the mTOR (mammalian target of rapamycin) kinase, a protein within all cells that regulates cell proliferation,

Wyeth Provides Update on FDA Review of the Torisel New Drug ...  -  Apr 6, 2007
PR Newswire (press release),About Torisel Torisel was designed to inhibit the mTOR (mammalian target of rapamycin) kinase, a protein within all cells that regulates cell proliferation,

Value of stent-coating drugs questioned  -  27 Mar 2007
EurekAlert (press release),Previous research has shown that rapamycin used in drug-eluting stents (DES) successfully reduces restenosis, or repetitive narrowing of the arteries.

LAM Lung Disease  -  Mar 20, 2007
WHOI,In further research, she found an anti-rejection drug for transplant patients, called rapamycin, could inhibit the growth of LAM cells by mimicking the

A Few Interesting Recent Research Publications  -  Mar 7, 2007
Methuselah Foundation,Most genes that affect longevity encode components of the target of rapamycin (TOR) pathway, thus revealing potential targets for pharmacological

Protein Found To Shield Pancreatic Cancer Cells From Self-Destruction  -  Mar 26, 2007
Medical News Today (press release),...cell death prevented by TG2 is independent of a prominent molecular pathway also known to regulate autophagy called the mammalian target of rapamycin.

Abraxis BioScience to Initiate Two Phase I/II Clinical Trials with ...  -  Mar 21, 2007
PipelineReview.com (press release),Abraxis also filed an IND for the mTOR inhibitor nab-rapamycin (ABI 009) in December 2006, the third investigational product based on the company's nab

Surgery for Congenital Heart Disease  -  Mar 9, 2007
The Journal of Thoracic and Cardiovascular SurgeryWhen a patient has transplant artery coronary disease, one thing that we have changed in the past 5 to 8 years is prescribing rapamycin.

Advances may curb fatal lung disease  -  Mar 19, 2007
Boston Globe,University of Pennsylvania, found that an FDA-approved drug called sirolimus (also known as rapamycin) could mimic the function of the missing tuberin.

New Anti-cancer Target Found  -  Mar 18, 2007
Medical News Today (press release),...mTOR (mammalian target of rapamycin) is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival,

Isotechnika reports full year and fourth quarter 2006 financial ...  -  Mar 16, 2007
CNW Telbec (Communiqués de presse),TAFA93, a pro-drug of rapamycin, is a novel small molecule mTOR inhibitor. This class is often used in combination with calcineurin inhibitors for

Abraxis BioScience Reports Record Revenue of $765 Million in 2006 ...  -  Feb 26, 2007
Genetic Engineering News (press release),Investigational New Drug (IND) applications were filed with the FDA for nab-docetaxel (ABI 008) and the mTOR inhibitor nab-rapamycin (ABI 009) in the fourth

Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis  -  Mar 8, 2007
AJP - Cell Physiology (subscription)...is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1.

Nanoscale packaging could aid delivery of cancer-fighting drugs  -  Feb 15, 2007
PhysOrg.com,Nature has produced a well-stocked arsenal of potent cancer-fighting compounds, including Taxol, first isolated from the Pacific yew tree, and rapamycin,

Nanoscale packaging could aid delivery of cancer-fighting drugs  -  Feb 15, 2007
Nanowerk LLC,Besides being safer and easier to administer, polymeric micelles maintain anti-cancer drugs like rapamycin in blood plasma for longer periods than do

Papers describe findings from University of Saarland, Germany, studies  -  Feb 1, 2007
Therapeutics Daily (subscription) (press release),Study 1: A new study, "Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation," is now available.

Research endeavors to make cancer treatment less expensive  -  Jan 30, 2007
49abcnews.com,Researchers at the University of Chicago are testing a combined treatment of the drug, Rapamycin, with grapefruit juice in patients with advanced cancer.

Doctors reduce birth defects in mice  -  Feb 16, 2007
Palo Alto Daily News,With that process in motion, they had a two-day window to restabilize the protein by injecting the pregnant mice with rapamycin - a molecule that restored

FDA Approves New Dosing Recommendations for RAPAMUNE in High ...  -  Feb 5, 2007
Drug Newswire (press release),RAPAMUNE(R) (sirolimus) is in a novel class of immunosuppressant agents called mammalian target of rapamycin (mTOR) inhibitors, a key regulatory enzyme

Rapamune OK'd for high-risk transplants  -  Feb 2, 2007
United Press InternationalThe drug, sirolimus, also known as rapamycin, received an indication to treat high-risk kidney-transplant patients -- individuals who are African-American,

FDA Approves New Dosing Recommendations for RAPAMUNE in High ...  -  Feb 2, 2007
PR Newswire (press release),About RAPAMUNE(R) RAPAMUNE(R) (sirolimus) is in a novel class of immunosuppressant agents called mammalian target of rapamycin (mTOR) inhibitors,

2006 drug approvals: finding the niche  -  Feb 1, 2007
Nature.com (subscription),Approval of several first-in-class cancer drugs, including Wyeth's mTOR (mammalian target of rapamycin) inhibitor, temsirolimus (Torisel), and the first

Juiced-Up Medicine  -  18 Jan 2007
ABC7Chicago.com,But now, researchers at the University of Chicago Hospitals are purposely pairing grapefruit juice with a medication known as sirolimus, or Rapamycin.

Relief Possible For High Costs Of Fighting Cancer  -  Jan 16, 2007
KDKA,Researchers in Chicago are testing rapamycin or rapamune, which is already FDA approved to prevent kidney transplant rejection.

Decorin-Mediated Regulation of Fibrillin-1 in the Kidney Involves ...  -  Jan 2, 2007
Am J Pathology (subscription)Accordingly, the enhanced synthesis of fibrillin-1 was blocked by rapamycin, an inhibitor of mTOR. Notably, IGF-I, which signals through the same pathway,

Thyroid hormone and Na + -K + -ATPase: more than simple transcription  -  Jan 10, 2007
AJP-Lung Physiology (subscription)...and increases protein synthesis by increasing both translation initiation and ribosome biogenesis via the mTOR (mammalian target of rapamycin) pathways.

"Silent" mutations are not always silent  -  Dec 21, 2006
Scientist,However, the haplotypes with C3435T proved more resistant against inhibition from CsA and verapamil, though not rapamycin, when they also included one or

Drug-eluting Stents Impede Coronary Collateral Function  -  Dec 27, 2006
MedPage Today,The authors said that evidence from animal studies suggests that sirolimus (Rapamycin) has anti-angiogenic properties, which would explain the apparent

FDA Grants Torisel NDA Priority Review Status  -  Dec 20, 2006
PipelineReview.com (press release),Torisel is the first mTOR (mammalian target of rapamycin) inhibitor to be filed for approval for the treatment of a cancer. It is an investigational drug

New Jersey business briefs  -  Dec 20, 2006
NorthJersey.com,The drug is the first of its kind, known as a mammalian target of rapamycin inhibitor, to be filed for approval to treat a cancer, Wyeth said.

Wyeth cancer drug gets priority review at FDA  -  Dec 20, 2006
Pharma Times (subscription),...drug class known as mTOR (mammalian target of rapamycin) inhibitors and is the first agent of its type to be filed for approval in a cancer indication.

Activation of Mammalian Target of Rapamycin Signaling Promotes ...  -  Dec 5, 2006
Am J Pathology (subscription)We hypothesized that mammalian target of rapamycin (mTOR) is activated in MCL and contributes to tumor proliferation and survival. ...

"Silent" mutations are not always silent  -  Dec 21, 2006
Scientist,...well these cells transported any of a variety of fluorescent molecules and tested how well P-gp inhibitors such as CsA, verapamil and rapamycin affected the ...

Investigational Temsirolimus Fails to Improve Outcomes in Women ...  -  Dec 19, 2006
DG NewsTemsirolimus is a specific inhibitor of mTOR (mammalian target of rapamycin), a protein that is required to sustain tumor growth. ...

New Jersey business briefs  -  Dec 20, 2006
NorthJersey.com,The drug is the first of its kind, known as a mammalian target of rapamycin inhibitor, to be filed for approval to treat a cancer, Wyeth said. ...

RESEARCH ROUNDUP  -  Dec 19, 2006
UPENN Almanac,...complex proteins—and furthermore, Dr. Krymskaya then discovered that growth can potentially be controlled by a drug (FDA-approved Rapamycin), which mimics ...

FDA Grants Torisel NDA Priority Review Status  -  Dec 19, 2006
Yahoo! News (press release)RCC. Torisel is the first mTOR (mammalian target of rapamycin) inhibitor to be filed for approval for the treatment of a cancer. ...

Wyeth cancer drug gets priority review at FDA  -  Dec 20, 2006
Pharma Times (subscription),...which has been filed for the treatment of advanced renal cell carcinoma, comes from a drug class known as mTOR (mammalian target of rapamycin) inhibitors and ...

Wyeth’s Renal Cell Carcinoma Drug Gets NDA Priority Review ...  -  Dec 19, 2006
Genetic Engineering News (press release),Torisel™ (temsirolimus) is the first mTOR (mammalian target of rapamycin) inhibitor to be filed for approval for the treatment of a cancer, the company ...

Notable advances  -  Nov 29, 2006
Nature.com (subscription),Rapamycin, an mTOR inhibitor, blocks this effect. The results suggest a possible target for obesity drugs. (Science 312, 927–930). ...

Researchers Make Progress Against Often Overlooked, Deadly Lung ...  -  Dec 10, 2006
Medical News Today (press release),...complex proteins - and furthermore, Krymskaya then discovered that growth can potentially be controlled by a drug (FDA-approved Rapamycin), which mimics the ...

Quest PharmaTech Strengthens its Patent Protection for SonoLight ...  -  Dec 5, 2006
Canada NewsWire (press release),In addition to the SonoLight and Bionex related patents, the Company also has a pending patent entitled "Rapamycin Peptides Conjugates Synthesis and Uses ...

Kidney Progress: Drug slows cyst growth  -  Nov 24, 2006
Science NewsMeanwhile, several other drugs, including rapamycin, octreotide, and tolvaptan, that succeeded in animal tests for PKD are now being tested in people. ...

Promising Treatment For High Risk Kidney Recipients In First Year ...  -  Nov 24, 2006
Medical News Today (press release),...marketed by Wyeth Pharmaceuticals as Rapamune®, is in a novel class of immunosuppressant agents called mammalian target of rapamycin (mTOR) inhibitors, a key ...

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional